A phase I/II study of olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC)

Trial Profile

A phase I/II study of olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC)

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Olaparib (Primary) ; Antineoplastics; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Acronyms ORCA
  • Most Recent Events

    • 11 May 2012 Trial phase changed from I to I/II as reported by as reported by United Kingdom Clinical Research Network record.
    • 11 May 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by United Kingdom Clinical Research Network record.
    • 15 Dec 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01491139).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top